Search Results - "VON STRITZKY, Berndt"

Association of low ankle brachial index with high mortality in primary care by DIEHM, Curt, LANGE, Stefan, DARIUS, Harald, PITTROW, David, VON STRITZKY, Berndt, TEPOHL, Gerhart, HABERL, Roman L, ALLENBERG, Jens Rainer, DASCH, Burkhard, TRAMPISCH, Hans Joachim

“…We aimed to assess the increased risk of death and severe vascular events in elderly individuals with subclinical or manifest peripheral arterial disease…”
Get full text

High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study by Diehm, Curt, Schuster, Alexander, Allenberg, Jens R., Darius, Harald, Haberl, Roman, Lange, Stefan, Pittrow, David, von Stritzky, Berndt, Tepohl, Gerhart, Trampisch, Hans-Joachim

“…We aimed to obtain reliable data on the epidemiology, co-morbidities and risk factor profile of peripheral arterial disease (PAD) in general medical practise…”
Get full text

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice by Parhofer, Klaus G., von Stritzky, Berndt, Pietschmann, Nicole, Dorn, Cornelia, Paar, W. Dieter

“…Background Several lipid guidelines recommend that proprotein convertase subtilisin/kexin type 9 inhibitors should be considered for patients with…”
Get full text

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial by Moriarty, Patrick M., MD, Parhofer, Klaus G., MD, Babirak, Stephan P., MD, PhD, deGoma, Emil, MD, Duell, P. Barton, MD, Hohenstein, Bernd, MD, Ramlow, Wolfgang, MD, Simha, Vinaya, MD, Steinhagen-Thiessen, Elisabeth, MD, Thompson, Paul D., MD, Vogt, Anja, MD, von Stritzky, Berndt, MD, Du, Yunling, PhD, Manvelian, Garen, MD

“…Background Many patients with heterozygous familial hypercholesterolemia (HeFH) fail to reach optimal low-density lipoprotein cholesterol (LDL-C) levels with…”
Get full text

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial by Moriarty, Patrick M, Parhofer, Klaus G, Babirak, Stephan P, Cornier, Marc-Andre, Duell, P Barton, Hohenstein, Bernd, Leebmann, Josef, Ramlow, Wolfgang, Schettler, Volker, Simha, Vinaya, Steinhagen-Thiessen, Elisabeth, Thompson, Paul D, Vogt, Anja, von Stritzky, Berndt, Du, Yunling, Manvelian, Garen

“…To evaluate the effect of alirocumab on frequency of standard apheresis treatments [weekly or every 2 weeks (Q2W)] in heterozygous familial…”
Get full text

Relationship between lipid parameters and the presence of peripheral arterial disease in elderly patients by Diehm, Curt, Lange, Stefan, Trampisch, Hans Joachim, Haberl, Roman, Darius, Harald, Stritzky, Berndt von, Pittrow, David, Tepohl, Gerhart, Allenberg, Jens Rainer

“…SUMMARY Conclusion: These findings are in contrast to previous studies. While lipid levels alone cannot be used for supporting the PAD diagnosis or the risk…”
Get full text

Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy by Bramlage, Peter, Bluhmki, Tobias, Rathmann, Wolfgang, Kaltheuner, Matthias, Beyersmann, Jan, Danne, Thomas

“…Highlights • Predictors for discontinuation of basal supported oral therapy in type 2 diabetes patients. • Data from the German DIabetes Versorgungs-Evaluation…”
Get full text

Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study by Moebus, Susanne, Balijepalli, Chakrapani, Lösch, Christian, Göres, Laura, von Stritzky, Bernd, Bramlage, Peter, Wasem, Jürgen, Jöckel, Karl-Heinz

“…Based on the AHA/NHLBI-definition three out of five cardiometabolic traits must be present for the diagnosis of the metabolic syndrome (MetS), resulting in 16…”
Get full text

Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle–brachial index (ABI) and high homocysteine level by Lange, Stefan, Trampisch, Hans Joachim, Haberl, Roman, Darius, Harald, Pittrow, David, Schuster, Alexander, von Stritzky, Berndt, Tepohl, Gerhart, Allenberg, Jens Rainer, Diehm, Curt

“…Previous studies in selected patient samples suggested a high risk for total mortality and cardiovascular (CV) morbidity associated not only with symptomatic,…”
Get full text

High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes by Lange, Stefan, Diehm, Curt, Darius, Harald, Haberl, Roman, Allenberg, Jens Rainer, Pittrow, David, Schuster, Alexander, von Stritzky, Berndt, Tepohl, Gerhart, Trampisch, Hans Joachim

Get full text

Prevalence of symptomatic and asymptomatic peripheral arterial disease in primary care patients by Aboyans, V., Lacroix, P., Laskar, M.

Get full text

Reply to “Prevalence of symptomatic and asymptomatic peripheral arterial disease in primary care patients” by Pittrow, David, Allenberg, Jens R., Darius, Harald, Haberl, Roman, Lange, Stefan, von Stritzky, Berndt, Tepohl, Gerhart, Trampisch, Hans-Joachim, Diehm, Curt

Get full text

Prevalence of symptomatic and asymptomatic peripheral arterial disease in primary care patients. Authors' reply by ABOYANS, V, LACROIX, P, TRAMPISCH, Hans-Joachim, DIEHM, Curt, LASKAR, M, PITTROW, David, ALLENBERG, Jens R, DARIUS, Harald, HABERL, Roman, LANGE, Stefan, VON STRITZKY, Berndt, TEPOHL, Gerhart

Get full text

Relationship between lipid parameters and the presence of peripheral arterial disease in elderly patients by Diehm, Curt, Lange, Stefan, Trampisch, Hans Joachim, Haberl, Roman, Darius, Harald, Stritzky, Berndt von, Pittrow, David, Tepohl, Gerhart, Allenberg, Jens Rainer

“…Conclusion: These findings are in contrast to previous studies. While lipid levels alone cannot be used for supporting the PAD diagnosis or the risk factor for…”
Get full text